A detailed history of Riverview Trust CO transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Riverview Trust CO holds 3,372 shares of BMY stock, worth $194,496. This represents 0.15% of its overall portfolio holdings.

Number of Shares
3,372
Previous 4,636 27.26%
Holding current value
$194,496
Previous $192,000 9.38%
% of portfolio
0.15%
Previous 0.18%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 17, 2024

SELL
$39.66 - $51.75 $50,130 - $65,412
-1,264 Reduced 27.26%
3,372 $174,000
Q2 2024

Jul 16, 2024

BUY
$40.25 - $52.99 $55,867 - $73,550
1,388 Added 42.73%
4,636 $192,000
Q1 2024

Apr 12, 2024

SELL
$47.98 - $54.4 $51,866 - $58,806
-1,081 Reduced 24.97%
3,248 $176,000
Q3 2023

Oct 17, 2023

SELL
$57.89 - $64.73 $14,125 - $15,794
-244 Reduced 5.34%
4,329 $251,000
Q2 2023

Jul 17, 2023

SELL
$63.71 - $70.74 $50,585 - $56,167
-794 Reduced 14.79%
4,573 $292,000
Q4 2022

Jan 25, 2023

SELL
$68.48 - $81.09 $44,991 - $53,276
-657 Reduced 10.91%
5,367 $386,000
Q3 2022

Oct 27, 2022

BUY
$0.13 - $76.84 $115 - $68,157
887 Added 17.27%
6,024 $428,000
Q1 2022

Apr 21, 2022

BUY
$61.48 - $73.72 $93,757 - $112,423
1,525 Added 42.22%
5,137 $375,000
Q4 2021

Jan 19, 2022

BUY
$53.63 - $62.52 $84,574 - $98,594
1,577 Added 77.49%
3,612 $225,000
Q3 2021

Oct 14, 2021

BUY
$59.17 - $69.31 $87,039 - $101,955
1,471 Added 260.82%
2,035 $120,000
Q2 2020

Jul 08, 2020

SELL
$54.82 - $64.09 $3,453 - $4,037
-63 Reduced 10.05%
564 $33,000
Q4 2018

Feb 12, 2019

BUY
$48.76 - $63.23 $30,572 - $39,645
627 New
627 $33,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Riverview Trust CO Portfolio

Follow Riverview Trust CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Riverview Trust CO, based on Form 13F filings with the SEC.

News

Stay updated on Riverview Trust CO with notifications on news.